Erratum in: Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits

Erratum in: “Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits” Hyeong Min Kim, Young Joo Park, Simin Lee, Joo Young Son, Hye Kyoung Hong, Min Hee Ham, Xuanyou Jin, Jae Yong Chung, Kyu Hyung Park, Ki Dong Park, and Se Joon Woo (Transl Vis Sci Technol. 2020;9(4):7), https://doi.org/10.1167/tvst.9.4.7. 

The Figure 1 and Figure 2 images and the Figure 2 legend have been corrected in the article online. 

Original Figure 1.

 

Corrected Figure 1.

 

Original Figure 2.

 

The efficacy of the conventional dose and the 10-fold dose in the retina, with reference to the measured concentration of four rabbit eyes at 30 and 60 days after injection. The concentration level known to inhibit at least 50% of VEGF-A in vitro is 27 ng/mL, and we estimated the duration of retinal concentration predicted above 27 ng/mL (red line). White dots are the observed data from the conventional dose, and the following linear trend line is drawn. Black dots are the observed data from the 10-fold dose, and the following linear trend line is drawn. Linear trends are drawn rather than exponential curves because the exponential curves after 30 days after injection are similar to linear lines. The calculated duration of the effective concentration level of ranibizumab in the retina is 1315 hours (55 days) with the conventional dose and 2393 hours (100 days) with the 10-fold dose, approximately twice as long.

 

Corrected Figure 2.

 

The efficacy of the conventional dose and the 10-fold dose in the retina, with reference to the measured concentration of four rabbit eyes post-injection. The concentration level known to inhibit at least 50% of VEGF-A in vitro is 27 ng/mL, and we estimated the duration of retinal concentration predicted above 27 ng/mL (red line). White dots are the observed data from the conventional dose, and the black dots are the observed data from the 10-fold dose. (A) Exponential trends of retinal ranibizumab concentrations were drawn after including the early time points and excluding 60 days post-injection for 10-fold dose and 30-days for the conventional dose. The calculated duration of the effective concentration level of ranibizumab in the retina is 615 hours (25.6 days) with the conventional dose and 970 hours (40.4 days) with the 10-fold dose, approximately 1.6 times longer. (B) As the biexponential decline could be assumed when the late phase data were included, additional linear trends of retinal ranibizumab concentrations were drawn to reveal only the late phase trends and the crossing points with the concentration of 27 ng/mL. This figure excluded the early time points and included only 30 days and 60 days post-injection. The calculated duration of the effective concentration level of ranibizumab in the retina is 1315 hours (55 days) with the conventional dose and 2393 hours (100 days) with the 10-fold dose, approximately twice longer.

 

View Original Article